Results 131 to 140 of about 10,258 (173)

Higher-Order Structure Characterization of NKG2A/CD94 Protein Complex and Anti-NKG2A Antibody Binding Epitopes by Mass Spectrometry-Based Protein Footprinting Strategies

Journal of the American Society for Mass Spectrometry, 2021
NK group 2 member A (NKG2A), an immune checkpoint inhibitor, is an emerging therapeutic target in immuno-oncology. NKG2A forms a heterodimer with CD94 on the cell surface of NK and a subset of T cells and recognizes the nonclassical human leukocyte antigen (HLA-E) in humans.
Guodong Chen, Richard Y-C Huang, Natalie Bezman   +2 more
exaly   +3 more sources

NKG2A blocks the anti-metastatic functions of natural killer cells

Cancer Cell, 2023
Pancreatic ductal adenocarcinoma (PDAC)-derived liver metastasis represents a major unmet medical need. Liu et al. show that circulating tumor cells (CTCs) from the hepatic portal vein (HPV), and not from primary or metastatic sites, are protected from natural killer (NK) cells through the NKG2A/HLA-E axis.
Florent, Carrette, Eric, Vivier
openaire   +2 more sources

Permanent silencing of NKG2A expression for cell-based therapeutics

Journal of Molecular Medicine, 2008
Natural killer (NK) and T-cell cytotoxicity is significantly reduced by signaling via CD94/NKG2A receptors. High levels of NKG2A on NK cells have been shown to compromise the graft-versus-leukemia effect in hematopoietic stem cell transplantation.
Constança, Figueiredo, Axel, Seltsam, Rainer, Blasczyk   +2 more
openaire   +2 more sources

NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody

Molecular Therapy
Natural killer (NK) cells eliminate infected or cancer cells via their cytotoxic capacity. NKG2A is an inhibitory receptor on NK cells and cancer cells often overexpress its ligand HLA-E to evade NK cell surveillance. Given the successes of immune checkpoint blockade in cancer therapy, NKG2A is an interesting novel target.
Ying Gong, Gérard M J Bos, Wilfred T V Germeraad   +2 more
exaly   +3 more sources

Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board

Trends in Immunology, 2019
Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential in cancer therapy. An article by the Vivier group (Cell 2018;175:1731-1743) shows that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible in T cells, results in benefits against poor prognosis tumors.
Mingari, Maria Cristina, Pietra, Gabriella, Moretta, Lorenzo   +2 more
openaire   +2 more sources

The NKG2A immune checkpoint — a new direction in cancer immunotherapy

Nature Reviews Clinical Oncology, 2019
Inhibition of the NKG2A immune checkpoint restores natural killer cell and T cell effector function in preclinical cancer models. In addition, NKG2A blockade in combination with other therapeutic antibodies is showing encouraging responses in a subset of patients with metastatic colorectal or head and neck cancer.
Benjamin C, Creelan, Scott J, Antonia
openaire   +2 more sources

Is CD94/NKG2A a Novel Target for Lymphoid Malignancies Immunotherapy?.

Blood, 2006
Abstract Background: Natural killer (NK)-cell receptors (NKRs) on CD8+ T cells can modulate antigen-specific T cell activity but their function and rules that govern their expression remain unclear. Among NKRs heterodimers CD94-NKG2 form either an inhibitory or an activating receptor, depending on whether CD94 associates with NKG2A or ...
Donata Urbaniak-Kujda, Jaroslaw Dybko, Iwona Prajs, Marek Kielbinski, Beata Tomaszewska-Toporska, Katarzyna Kapelko-Slowik, Kazimierz Kuliczkowski   +6 more
openaire   +2 more sources

A Higher Frequency of NKG2A+ than of NKG2A- NK Cells Responds to Autologous HIV-Infected CD4 Cells irrespective of Whether or Not They Coexpress KIR3DL1.

Journal of virology, 2015
Epidemiological and functional studies implicate NK cells in HIV control. However, there is little information available on which NK cell populations, as defined by the inhibitory NK cell receptors (iNKRs) they express, respond to autologous HIV-infected CD4(+) (iCD4) T cells.
Irene, Lisovsky, Gamze, Isitman, Rujun, Song, Sandrina, DaFonseca, Alexandra, Tremblay-McLean, Bertrand, Lebouché, Jean-Pierre, Routy, Julie, Bruneau, Nicole F, Bernard   +8 more
openaire   +2 more sources

CD94-NKG2A receptors regulate antiviral CD8+ T cell responses

Nature Immunology, 2002
CD8(+) T lymphocytes mediate immunosurveillance against persistent virus infections and virus-induced neoplasia. Polyoma virus, a highly oncogenic natural mouse DNA virus, establishes persistent infection, but only a few mice are highly susceptible to tumors induced by the virus.
Janice M, Moser, James, Gibbs, Peter E, Jensen, Aron E, Lukacher   +3 more
openaire   +2 more sources

Molecular cloning of mouse NKG2A and C

Immunogenetics, 1999
E T, Silver, J C, Lau, K P, Kane
openaire   +2 more sources